ERBB2 and breast carcinoma: These clinical successes have established docetaxel as a standard-of-care chemotherapeutic; it is frequently used either alone or in combination (e.g., with anthracyclines or platinum agents) for high-risk early breast cancer [8] and as a first-line treatment for HER2-positive recurrent or metastatic disease in combination with trastuzumab and pertuzumab [11].